According to the International Society of Blood Transfusion Working Party on Red Cell Immunogenetics and Blood Group Terminology, more than 340 blood group antigens are currently recognized. 1, 2 The frequencies of these antigens vary among communities and ethnic groups. For example, the prevalence of the Di a antigen is 6.4% to 14.5% in Korea and 5.5% in Japan, but this antigen is very rare in people of European or African descent. [3] [4] [5] In contrast, the prevalence of the K antigen is 9% in Europeans and 1.5% in Africans, but this antigen is extremely rare in people of East Asian descent. 4 Immunization as a result of transfusion, pregnancy, or other events can produce unexpected RBC antibodies. For naturally occurring antibodies, a specific immunizing event may not be identifiable. 4 A transfusion of the corresponding specific antigen-negative blood can prevent adverse transfusion reactions in patients who have unexpected antibodies.
Several registries have been established in the field of transfusion medicine, including the blood donor registry, hemovigilance program, and massive transfusion registry. 6, 7 To ensure a stable supply of blood units for patients with RBC antibodies, knowing the probability of obtaining a compatible blood unit is important. Many countries have established rare donor programs to ensure the availability of rare blood units. The numbers of rare donors and frozen RBC units of several countries were described in previous literatures. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] The definition of rare blood depends on the prevalence of specific antigens in a population. To establish a rare donor program, accurate information about the frequencies of RBC antigens in specific populations is required. Beginning in July 2013, the Korean national registry from recipients' viewpoint, named the Korean Rare Blood Program, requested that every hospital blood bank in Korea voluntarily register transfusion recipients with unexpected antibodies on the SafeBlood website (http:// safeblood.or.kr). In the present study, we utilized data from the Korean national registry to investigate the distribution of unexpected antibodies and estimate the frequencies of specific antigen-negative blood units.
Materials and Methods

Study Population
The Korean national registry includes a database of more than 3,500 cases from more than 20 institutes, collected from July 2013 to the present. In the present study, data registered between July 2013 and April 2016 were analyzed. The database includes the specificities of identified antibodies, methods of antibody screening and antibody identification, and antigen test methods. It also contains information about the number of RBC units requested, antigen tested, and obtained. For patients examined over multiple days, each day was considered to be an independent case and registered separately ❚Figure 1❚.
A separate "referred" registry includes cases that were considered difficult to evaluate. For cases that the blood bank cannot analyze using routine serologic tests, specimens are sent to the Seoul National University Bundang Hospital (SNUBH) laboratory for further evaluation. Examples include the ABO subgroup, variants of RhD, and complex antibodies. The SNUBH laboratory performs additional serologic tests and/or molecular analyses. The data were analyzed briefly to obtain information about the geographic distribution of participating institutions. The study was approved by the institutional review board of Seoul National University Bundang Hospital.
Antibody Screening, Antibody Identification, and Antigen Testing
The methods used for antibody screening, antibody identification, and antigen testing for each case were recorded on the website. The methods included column agglutination (manually or with an automated system), ❚Figure 1❚ Registration form on the website of the Korean national registry. Items include: name of institution; input date; name of antibody; method of antibody screening; antibody identification and/or antigen test; and number of requested, antigen-tested, and actually obtained RBC units.
the tube method, and the microplate-based method (manually or with an automated system). More than one option could be selected when an institute used multiple methods.
Estimation of Antibody Distribution and Calculation of Specific Antigen-Negative Frequencies
Antibodies were sorted according to specificity, and alloantibodies and autoantibodies were sorted separately. When an antigen test was performed, the hospital indicated whether it was performed internally or referred to another laboratory. Data on the number of RBC units requested, antigen tested, and obtained were reviewed and analyzed. The frequencies of specific antigen-negative units were calculated using the following equation:
Specific antigen negative frequency
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Next, the number of units required to obtain one specific antigen-negative unit was calculated using the following equation:
No. of RBC units required Specific antige = 100 n n negative frequency % ( ) Because it is impossible to obtain a fraction of a unit, the calculated value of units required to obtain one specific antigen-negative unit was rounded up to the next whole number. These calculations were performed only in cases in which hospitals performed antigen tests. Cases in which antigen tests were performed by other laboratories were excluded due to uncertainty regarding the number of RBC units tested. Cases with 100% frequencies of specific antigen-negative units were also excluded because these RBC units may have been previously tested and preselected by the Blood Information Sharing System (BISS) of the Korean Red Cross Blood Services or by community blood centers. Cases with multiple alloantibodies were included in calculations in which all of the antigens corresponding to the identified antibodies were tested. All of the tested antigens were selected on the website including the following antigens recommended by the United States 
Results
Geographic Distribution
Between July 2013 and April 2016, 3,513 cases were registered by 22 institutes (Supplemental Table S1 ; all supplemental materials can be found at American Journal of Clinical Pathology online). The median number of beds per institute was 982. With regard to geographic distribution, 10 institutes were located in Seoul, six in Gyeonggi-do, two in Busan, and four in other areas. The registry of referred cases included 215 cases from 37 institutes (14 institutes in Seoul, nine in Gyeonggi-do, three in Gwangju, three in Busan, two in Gyeongsangnam-do, and six in other regions).
Overall Distribution of Unexpected Antibodies
Among a total of 3,513 cases registered, there were 177 cases with insufficient information for categorization and these were not analyzed further ❚Table 1❚. Of the remaining 3,336 registered cases, more than one-half (57.1%) had single alloantibodies and nearly one-third (31.7%) had multiple alloantibodies. The remaining cases represented autoantibodies (1.9%) or unidentified specificities (311 cases, 9.3%).
Antibody Screening, Antibody Identification, and Antigen Testing
The methods used for antibody screening, antibody identification, and antigen testing were investigated. Considering manual methods and an automated system together, the column agglutination technique was the most commonly used antibody screening and identification method (3, 199 See Table 3 for details on multiple alloantibodies.
2,410/3,513 cases, 68.6% for identification). Excluding 1,224 cases in which antigen testing was not performed, the tube method was the most common antigen testing method (1,897/2,289 cases, 82.9%). Several institutes used a combination of methods.
Distribution of Alloantibodies and Specific AntigenNegative Frequencies
Data on the distribution of alloantibodies with specificity were arranged according to frequency in ❚Table 2❚. The most common single alloantibody was anti-E, representing over 40% of cases, followed by anti-Le a , approximately 16% of cases. Anti-Di a alloantibody was present in 58 (3%) cases, making it the eighth most common single alloantibody. Of cases with multiple alloantibodies, anti-E with anti-c accounted for more than half (57.4%) and anti-C with anti-e for approximately 25% ❚Table 3❚.
The frequencies of specific antigen-negative blood units were calculated (Table 2 and Table 3 ). A total of 733 E-negative blood units were identified from 1,731 units tested (for E antigen), resulting in a frequency of 42.3% (or alternatively, three units were required to obtain one E-negative unit). Results for the other antigens are listed in Table 2 . The frequencies of the M, Jk b , and C antigens were relatively low (20.2%, 20.6%, and 17.9%, respectively). In cases requiring anti-C, anti-e, and anti-Jk a antibodies simultaneously, an average of 10 units was required to obtain one compatible blood unit.
Discussion
The Korean national registry began in 2013 and more than 3,000 cases have accumulated in the database. A previous study included only a few hundred cases in the database of Korean national registry during 8 months. 28 In the present study, beginning in 2013, 22 institutes from various regions in Korea registered data on the Korean national registry website. The median number of beds was 982, with 10 large-scale hospitals having more than 1,000 beds (data not shown). Based on the population distribution in Korea, the data collected in this study may be only partially representative of the entire country. Institutes in Gangwon-do and Jeolla-do did not contribute any registered data, and efforts to increase participation in these areas are warranted. In spite of this limitation, the present study is the most extensive to date. This nationwide study of recipients represents the distribution of unexpected antibodies and the frequencies of specific antigen-negative blood units in Korea. Considering the total number of cases identified as single and multiple antibodies, the most common antibodies were as follows: anti-E (1,498 (365 cases, 10.9%), anti-C (317 cases, 9.5%), anti-e (288 cases, 8.6%), and anti-M (184 cases, 5.5%) ( Table 2 and  Table 3 ). In another Asian population, that is, the Chinese population, the most common antibodies were as follows:
anti-E (26.4%), anti-D (19.1%), anti-M (9.7%), anti-C (4.7%), anti-c (4.3%), and anti-Le a (3.1%). 29 In both these Asian populations, antibodies of the Rh, Lewis, and MNS blood group system were common; however, unlike Caucasian population, antibodies of the Kell system were extremely rare. The present study is based on the most current database and includes a much larger number of cases than previous studies, 28 yielding more accurate results. A national registry of blood donors should be established to allow for quicker and easier identification of compatible blood units.
In total, 1,905 cases with single alloantibodies and 1,057 cases with multiple alloantibodies were identified ( Table 2 and Table 3 ). Obtaining compatible blood may be more difficult for cases with multiple alloantibodies than for those with single alloantibodies. The most commonly identified multiple alloantibodies were anti-E with c and anti-C with e, accounting for 82.0% of cases with multiple alloantibodies (Table 3 ). The remaining cases also had Rh antibodies, including the anti-E, anti-c, with antiLe a alloantibodies. Obtaining antigenic information on the Rh blood group system is important because a high proportion of the alloantibodies were directed against Rh antigens; however, a comprehensive study of the prevalence of Rh antigen combinations in the Korean population is not yet available. The Red Cross Blood Services in Korea began testing for C antigen and e antigen in all donor blood units in April 2013. The test for E antigen was added in July 2014 but was replaced by the test for c antigen in August 2015. Patients with the CDe phenotype, the most common Rh phenotype in the Korean population, can be exposed to c antigen and alloimmunized. Testing for E antigen was reintroduced in June 2016 due to high demand. Information about five Rh antigens (D, C, E, c, and e) is currently provided by BISS. 30 Based on this example, a database for various other antigens should be established. Results of the present study provide useful data to determine the order of priority.
We found that many cases had obtained RBC units that exceeded the number requested ( Table 2 and Table 3 ), likely because blood bank technicians were ensuring that the number of RBC units provided was sufficient to meet patient needs, but were uncertain how many units needed to be screened to fill the request. An accurate database with information about the frequencies of specific antigen-negative blood units is needed to reduce unnecessary antigen testing and prevent delays in the issuance of blood units to patients. This study provides information that may be useful to many medical institutes. In addition, in the context of donor recruitment and management, the frequencies of specific antigen-negative blood units are useful for developing strategies for recruiting blood donors to support patients with specific antibodies. For example, when one unit of RBCs is to be provided to a patient with anti-M, five donors should be recruited because the frequency of M-negative units is 20.2% (Table 2 ). This strategy could be utilized in other populations, taking into consideration their ethnicity and antigen frequencies.
The Di a antigen is very rare in Caucasian populations, but is relatively common in most Mongoloid (Korean, Japanese, Chinese, and South American Indian) populations. The anti-Di a alloantibody can cause hemolytic disease of the fetus and newborn and delayed hemolytic transfusion reactions. 31, 32 Considering the prevalence and clinical significance, it is important to detect the anti-Di a antibody in Korea. One approach is to add Di apositive RBCs as unexpected antibody screening panel cells. 33 Currently, some institutes in Korea perform the antibody screening using Di a -positive cells, but others do not. It has been reported that about 21% of institutes perform antibody screening using Di a -positive cells (four of 19 surveyed institutes, unpublished data). A previous study performed at a single institute analyzed the results of antibody screening and identification tests conducted between 2002 and 2012. 34 Antibody screening was performed using antigen panels that included commercially available Di a antigen-positive cells (Di a ; DiaMed, Murten, Switzerland). From a total of 156,161 cases, 1,326 cases (excluding overlapped cases from 1,918 cases) had unexpected antibodies and 83 cases (83/1,326, 6.3%, excluding eight from 91 cases, identified as anti-Di a together with other antibodies) had the anti-Di a alloantibody solely, the fourth most common antibody identified in that institute after anti-E, anti-E with anti-c, and anti-Le a . In the present study, the anti-Di a alloantibody was the tenth most common antibody (58/3,336, 1.7%, including all of the cases of single and multiple alloantibodies; Table 2 and  Table 3 ), which is less common than a previous report from the single institute using Di a -positive cells. 34 The cases of anti-Di a antibody in the present study were registered mainly by institutes using Di a -positive cells. The proportion of cases that were screened for anti-Di a was not available because the antigens included in screening panels used in each institutes were not recorded on the website. In some of the institutes using no Di a -positive cells, specimens of unsolved cases, such as unexpected hemagglutination in cross-matching, were sent to the SNUBH laboratory for further studies and this sometimes revealed cases of anti-Di a , described as the referred registry in the Materials and Methods section. If screening of all patients with a panel including Di a -positive cells is not economical, these cells should be used for patients with histories of multiple transfusions. 35 The Di a -positive frequency was calculated as 45.2% (Table 2) , which was higher than previous studies (6.4%-14.5%). 2, 3 The possible cause of this difference is that the methods of calculating the frequency was different or the number of tests was insufficient in the present study. Among 58 cases with anti-Di a , antigen tests for Di a were performed in only 17 cases and the Di a -negative frequency was calculated from only 31 tested units (Table 2) . It suggests that antigen typing for the Diego blood group system using anti-Di a antisera or molecular methods is not sufficiently implemented now. Efforts to detect the antiDi a alloantibody should be continued to limit adverse transfusion reactions.
The specific antigen-negative frequencies calculated in this study, which was based on serologic methods, were compared to results of a previous study conducted by Hong et al. 36 In that study, blood samples from 419 healthy blood donors were genotyped using the Lifecodes RBC/RBC-R typing kit (Immucor, Norcross, GA). We reviewed the RBC genotyping results of 306 RhD-positive donors from that study. To ensure that the proportions of RhD-positive and -negative donors reflected the general population in Korea, 113 RhD-negative donors were excluded from our assessment; the prevalence of RhD negativity is approximately 0.1 % in Korea. Calculation of the frequencies of specific antigen negativity by serologic methods and by genotyping yielded similar results ❚Table 4❚. Although it is difficult to compare the results directly, the discrepancy between phenotypes determined by serologic methods and predicted phenotypes from genotyping should be discussed. Discrepancies in the negative frequencies of the e, S, Fy b , and Di a antigens between serologic methods and genotyping were noted. The negative frequency of the e antigen was greater in the present study than in the earlier study. 36 A discrepancy between serologic antigen testing and genotyping results for the S antigen was observed in the previous study. 36 Discrepancies can be caused by variants of antigens, weak phenotypes, presence of autoantibodies, and mixed population of RBCs resulting from recent transfusion. 37 Additional possible explanations are selection bias, transient events, or the difference in test methods. In another study, 38 RBC genotyping was performed for various ethnic populations, including 1,033 Koreans, by the HEA BeadChip kit (Bioarray Solutions, Immucor, Warren, NJ), and the results were similar to the genotyping results from Hong et al. 36 Genotype-serotype discrepancies were detected in 4.5%, which may have been due to underlying genetic variation that is not targeted by the RBC genotyping kit. 38 That is, the polymorphisms tested may not be representative of the study population.
In transfusion medicine, results of molecular methods should be interpreted in the context of serology by an immunohematology specialist. 37 In the Korean national registry data, the most common antigen testing method was the tube method (82.9%); the estimation of specific antigen-negative frequencies in the present study reflects practical laboratory conditions and thus may be useful to many laboratories. This study was based on a much larger number of antigen-tested cases than previous studies in which serologic methods were used for antigen testing, 28 giving more reliable results.
The present study has a limitation stemming from the low number of tests in some cases. In cases of multiple antibodies, the number of antigens tested and obtained RBC units was low, except for the cases of anti-E and c and anti-C and e (Table 3 ). In cases of such Rh antigen combinations, data in Table 3 are more reliable than those in Table 2 . However, in other cases, we suggest that blood banks should refer to the frequencies of specific antigen-negative units from Table 2 to calculate the expected frequency of RBC units that are negative for multiple antigens, and not rely as heavily on Table 3 . To get closer to the true frequency for use as a reference database, the data of this Korean national registry should be accumulated continuously. Another limitation is that the specific procedures used to identify antibodies could not be identified based on the information available on the website. In cases with rare antibodies, recording of the specific methods and procedures is critical. Lastly, although all of the tested (phenotyped) antigens were selected on the website, the antigens included in screening panels of each institutes were not intended to be selected on the website (Figure 1 ). The registration form on the website should be revised to be able to estimate the proportion of the cases screened for anti-Di a by Di a -positive cells. In summary, the significance of this study is that it is based on a large national database and it provides reliable prevalence data for RBC antigens and antibodies, which are necessary for designing a suitable screening panel of cells for antibody testing, for designing and interpreting molecular analysis, and for developing blood donor recruitment and blood inventory management strategies. Collection of valuable information on a national database is a worthwhile initiative and should be continued to reflect the population of the entire country. An established national registry of blood donors would allow for quicker and easier identification of compatible blood units. The number of antigen tests varied according to the specificity of the antigens (see Table 2 ).
